Tag - AMYT


SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.